Orthofix International N.V. (OFIX) Position Lifted by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its position in shares of Orthofix International N.V. (NASDAQ:OFIX) by 4.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 245,495 shares of the medical device company’s stock after acquiring an additional 10,580 shares during the quarter. JPMorgan Chase & Co. owned approximately 1.35% of Orthofix International worth $11,654,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Pinebridge Investments L.P. raised its holdings in Orthofix International by 2.3% in the 2nd quarter. Pinebridge Investments L.P. now owns 2,378 shares of the medical device company’s stock worth $111,000 after acquiring an additional 53 shares during the last quarter. Arizona State Retirement System raised its holdings in Orthofix International by 1.1% in the 2nd quarter. Arizona State Retirement System now owns 9,400 shares of the medical device company’s stock worth $437,000 after acquiring an additional 100 shares during the last quarter. Victory Capital Management Inc. raised its holdings in Orthofix International by 1.2% in the 2nd quarter. Victory Capital Management Inc. now owns 32,089 shares of the medical device company’s stock worth $1,491,000 after acquiring an additional 365 shares during the last quarter. AJO LP raised its holdings in Orthofix International by 0.4% in the 2nd quarter. AJO LP now owns 169,162 shares of the medical device company’s stock worth $7,863,000 after acquiring an additional 702 shares during the last quarter. Finally, Voya Investment Management LLC raised its holdings in Orthofix International by 10.7% in the 2nd quarter. Voya Investment Management LLC now owns 8,622 shares of the medical device company’s stock worth $401,000 after acquiring an additional 832 shares during the last quarter. 94.61% of the stock is currently owned by institutional investors and hedge funds.

In other news, insider Bradley V. Niemann sold 5,547 shares of the business’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $52.08, for a total transaction of $288,887.76. Following the completion of the sale, the insider now owns 34,631 shares of the company’s stock, valued at approximately $1,803,582.48. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Brad Mason sold 5,000 shares of the business’s stock in a transaction on Tuesday, November 28th. The shares were sold at an average price of $53.48, for a total transaction of $267,400.00. Following the sale, the chief executive officer now directly owns 183,053 shares of the company’s stock, valued at approximately $9,789,674.44. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,347 shares of company stock valued at $802,144. 5.60% of the stock is currently owned by insiders.

Orthofix International N.V. (NASDAQ OFIX) traded down $0.36 during trading hours on Friday, reaching $53.90. 73,214 shares of the company’s stock were exchanged, compared to its average volume of 83,175. Orthofix International N.V. has a fifty-two week low of $33.51 and a fifty-two week high of $56.53. The company has a market cap of $989.21, a P/E ratio of 770.11, a PEG ratio of 2.36 and a beta of 0.14.

Orthofix International (NASDAQ:OFIX) last posted its earnings results on Monday, October 30th. The medical device company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.01. Orthofix International had a net margin of 0.33% and a return on equity of 10.26%. The business had revenue of $105.30 million during the quarter, compared to the consensus estimate of $100.67 million. During the same quarter in the previous year, the firm posted $0.36 EPS. The firm’s revenue was up 6.9% on a year-over-year basis. equities research analysts expect that Orthofix International N.V. will post 1.61 EPS for the current year.

OFIX has been the subject of a number of recent analyst reports. TheStreet lowered shares of Orthofix International from a “b” rating to a “c+” rating in a report on Tuesday, October 31st. Zacks Investment Research lowered shares of Orthofix International from a “buy” rating to a “hold” rating in a report on Wednesday, November 8th. BidaskClub upgraded shares of Orthofix International from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. Finally, BTIG Research set a $56.00 target price on shares of Orthofix International and gave the stock a “buy” rating in a research report on Monday, October 30th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $54.42.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/13/jpmorgan-chase-co-purchases-10580-shares-of-orthofix-international-n-v-ofix.html.

Orthofix International Company Profile

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Institutional Ownership by Quarter for Orthofix International (NASDAQ:OFIX)

Receive News & Ratings for Orthofix International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply